Počet záznamů: 1
Use of RLI-15 a clinical grade fusion protein with IL-15 superagonistic activity for the activation of anti-tumor immune response
- 1.Adkins, I., Sadílková, I., Hradilová, N., Tomala, J., Tomalová, B., Kovář, M., Mikysková, R., Reiniš, M., de Martynoff, G., Bechard, D., Moebius, U., Spíšek, R. Use of RLI-15 a clinical grade fusion protein with IL-15 superagonistic activity for the activation of anti-tumor immune response. Cancer Research. 2018, 78(13 S). ISSN 0008-5472. E-ISSN 1538-7445. Dostupné z: doi: 10.1158/1538-7445.AM2018-3775
Počet záznamů: 1